The history of biomedical product regulation is a history of hard-won progress. Often, only after tragedy, has regulatory statute caught up to drugs with horrid side effects or medical devices that offer no benefit but may do harm. Harmful or questionable products slip through cracks in regulatory statutes and are brought to market quickly and prolifically, while regulators play catch up and must demonstrate harms before being enabled to police or regulate them. A notable present-day example is e-cigarettes, a multi-billion-dollar industry with clearly questionable marketing practices, which arrived and grew quickly without any form of premarket regulatory obligation. Similarly, digital health tools are proliferating, and most are yet to be subject to premarket regulation. This chapter provides a brief history of biomedical-products regulation with a focus on benefit-risk determination and its impacts on regulatory policy.